Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Oct 28 2022

Full Issue

Walgreens Pharmacy Staff Will Be Allowed To Work More Slowly

NBC News reports that Walgreens is going to stop judging pharmacy staff performance on speed or "task-based metrics," with the pharmacy giant saying that evaluations will center on patient support and quality instead. Separately, a patient died in an Alzheimer's drug trial, sparking risk concerns.

NBC News: Walgreens Will Stop Judging Its Pharmacy Staff By How Fast They Work

Walgreens, the country’s second-largest pharmacy chain, announced Wednesday that it is eliminating “task-based metrics” from performance evaluations to allow its pharmacy staffers to “place even greater focus on patient care.” They will now be evaluated “solely on the behaviors that best support patient care and enhance the patient experience,” Walgreens said in a news release. (Kaplan, 10/27)

In other pharmaceutical news —

Stat: Death Of Patient In Alzheimer’s Trial Raises Question Of Possible Risks

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned. (Mast, 10/28)

On drug use and addiction —

Reuters: McKinsey Reaches Deal With U.S. Local Governments Over Opioids 

Leading consulting firm McKinsey & Co has agreed to settle claims by hundreds of U.S. local governments and school districts around the country that it fueled an epidemic of opioid addiction through its work for bankrupt OxyContin maker Purdue Pharma LP and other drug companies. The deal was disclosed in a court filing Wednesday evening in San Francisco federal court. Its terms were not made public, and McKinsey and a lawyer for the settling plaintiffs did not immediately respond to requests for comment. (Pierson, 10/27)

Anchorage Daily News: A Year After Fentanyl Killed A 22-Year-Old Alaskan, A Bill Named After Him Moves Forward In Congress

A bill named after a 22-year-old Alaskan who died of a fentanyl overdose took a step forward this week, with companion legislation to a U.S. Senate proposal now introduced in the House. Robert “Bruce” Snodgrass of Anchorage died in October 2021. In the year since, his mother helped advocate for legislation to spread awareness about deadly synthetic opioids like fentanyl. (Rogerson, 10/27)

AP: Parents Sue Over Son's Death After He Took Kratom Supplement 

Dana and John Pope had never heard of kratom before their 23-year-old son, Ethan, was found dead on the kitchen floor in his apartment last December with his puppy by his side. Extracted from the leaves of a tropical tree native to Southeast Asia, kratom is used to make capsules, powders and liquids and is marketed as an aid for pain, anxiety and drug dependence. In Georgia and some other states, it’s often sold at gas stations and smoke shops. ... The lawsuit was originally filed in May and an expanded version was filed earlier this week. The lawyers who filed the suit said they want to send a message that kratom is unsafe for human consumption. (Brumback, 10/27)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF